Filed under: Earnings reports, Analyst upgrades and downgrades, Technical Analysis, Stocks to Buy

eResearchTechnology (NASDAQ: ERES) provides technology and services to the pharmaceutical, biotechnology and medical device industries. The company streamlines the clinical trials process by enabling customers to automate the collection, analysis and distribution of data in all phases of clinical development. The firm’s flagship product, EXPeRT, processes and interprets electrocardiogram data collected during trials, to insure cardiac safety. eResearchTechnology operates in the US and the UK.

The firm pleased investors earlier in the week, when it reported Q1 EPS of 11 cents and revenues of $33.7 million. Wall Street analysts had been looking for nine cents and $31.6 million. Management also guided Q2 EPS to 10-12 cents (ten cent Street), Q2 revenues to $34-$36 million ($32.95M Street), FY08 EPS to 44-49 cents (44 cent Street) and FY08 revenues to $133-$140 million ($134.99M Street). Friedman Billings subsequently reiterated its “outperform” rating on the shares and boosted its price target to $18.

Continue reading eResearchTechnology (ERES): Shares define bullish ‘flag’ consolidation pattern

Permalink | Email this | Comments

Via [bloggingstocks]

Share This

This entry was posted on Monday, May 12th, 2008 at 4:19 am and is filed under Stocks Money News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.